Newsfeed

Historic debut in srilanka
Published: 25 June, 2023

Olaparib Tablet makes historic debut in Sri Lanka, Revolutionizing Cancer Treatment Landscape

Jenphar Bangladesh Limited has achieved a remarkable milestone by registering its groundbreaking oncology product Olaparib INN Tablet (Juparib 100 mg & 150 mg) in Sri Lanka. With its recent registration approval, Olaparib…

View details
Oncology market with a new option for Breast Cancer
Published: 25 June, 2023

Jenphar has stepped up in the oncology market with a new option for Breast Cancer

Jenphar Bangladesh Limited, has stepped up in the oncology market with its new product HER-2N 200 tablet, preparation of Ribociclib Succinate 200 mg Tablet. HER-2N is a CDK4/6 inhibitor that is indicated…

View details
Launched new oncology brand for Sarcoma & kidney Cancer
Published: 25 June, 2023

Jenphar has launched new oncology brand for Sarcoma & kidney Cancer

Jenphar Bangladesh Limited is pleased to announce the successful launch of new oncology product Pazopanib Hydrochloride 400 mg tablet as the brand name of Zotrix 400 tablet. Pazopanib Hydrochloride is an oral,…

View details
GMP Certificate from Syria
Published: 25 June, 2023

Jenphar Bangladesh achieves GMP Certificate from Ministry of Health (MOH), Syria

Jenphar manufacturing site, a state of art facility achieves a triumph by registering their company in Syria which has opened a new door for export. The delegates of Syrian Ministry of Health…

View details
news_3
Published: 25 June, 2023

Blood Donation Program

View details

Radiant Affiliated Companies